Chiesi has been developing medicines to treat respiratory disease for more than 30 years, in area of Slovakia from 2005. Thanks to modern treatments, patients with asthma or chronic obstructive pulmonary disease (COPD) are able to live more active lives with greater self-confidence. After all, to breathe is to live.
is one of the most common chronic diseases found in children and young people, although the number of adults and older people being diagnosed is also on the rise. The WHO estimates that there are around 235 million asthmatics worldwide.
As a chronic inflammatory disease involving extreme hypersensitivity of the airways, the typical symptoms of asthma are recurrent and sudden, including shortness of breath, coughing, wheezing and a tight feeling in the chest. These symptoms often arise at night and in the early hours of the morning, and vary widely depending on the severity of the disease.
(Foster®; Foster Nexthaler®;Trimbow®; Budiair®; Atimos®)
Chronic obstructive pulmonary disease
or COPD, is one of the most common diseases of adults. It affects around 340 million people worldwide.
It is assumed that, around 5 to 10% of adults aged > 40 suffer from a chronic obstructive lung disease. In statistics regarding the most common causes of death, COPD is currently ranked fourth (data from 2015).
The umbrella term “chronic obstructive pulmonary disease” covers a number of lung diseases. These include chronic bronchitis, a very common disease that is defined as “coughing and production of sputum on most days for at least three months in two consecutive years” (Source: WHO). Chronic bronchitis often progresses to become chronic obstructive bronchitis, which in a large number of cases is related to lung emphysema, in which there is hyperinflation of the lungs.
(Foster®; Foster Nexthaler®; Trimbow®; Budiair®; Atimos®)
To know more, go to: http://www.rozdychajto.sk/